STEPS

New Drug Reviews

Rifaximin (Xifaxan) for Irritable Bowel Syndrome

 

Am Fam Physician. 2017 Feb 15;95(4):258-259.

Rifaximin (Xifaxan) is an oral antibiotic previously marketed for the treatment of traveler's diarrhea and hepatic encephalopathy. It is now also labeled for the treatment of irritable bowel syndrome (IBS) with diarrhea.1 Rifaximin has activity against anaerobic, gram-positive, and gram-negative bacteria, including Clostridium difficile. It is not systemically absorbed and is active only in the gastrointestinal tract. It may work by reducing bacterial byproducts and altering intestinal microbiota.2

 Enlarge     Print

DrugDosageDose formCost*

Rifaximin (Xifaxan)

500 mg orally three times per day for 14 days

500 mg tablets

$1,400


*—Estimated retail price of 14 days of treatment based on information obtained at http://www.goodrx.com (accessed December 6, 2016).

DrugDosageDose formCost*

Rifaximin (Xifaxan)

500 mg orally three times per day for 14 days

500 mg tablets

$1,400


*—Estimated retail price of 14 days of treatment based on information obtained at http://www.goodrx.com (accessed December 6, 2016).

SAFETY

Serious adverse effects from rifaximin are rare (less than 1%).3 It should not be used in patients with severe hepatic impairment and rarely causes C. difficile–associated colitis. Rifaximin does not alter the pharmacokinetics of a single dose of oral contraceptives, but its effect on daily oral contraceptive use is uncertain. Taking rifaximin with cyclosporine (Sandimmune) dramatically increases systemic availability of rifaximin (124-fold),1 although the clinical significance of this is unknown.

Rifaximin is a U.S. Food and Drug Administration pregnancy risk category C drug, and its safety for use in breastfeeding women is unknown.

TOLERABILITY

Rifaximin is well tolerated, which is partially because of no systemic absorption. In controlled trials, the discontinuation rates because of adverse reactions were similar between rifaximin and placebo (0.4%).1 Rare adverse effects include diarrhea, loss of taste, anorexia, nausea, and irritation of nasal passages.1

EFFECTIVENESS

In those who have IBS with diarrhea that consists of abdominal symptoms and more than three bowel movements per day, rifaximin improves the patient's global impression of IBS symptoms compared with placebo. In two randomized trials with a total of 1,258 patients who had IBS with diarrhea, those taking rifaximin were more likely than those taking placebo to report adequate symptom relief after one month (41% vs. 31%; P < .001).4 For every 10 patients treated, one additional patient reported relief (number needed to treat [NNT] = 10; 95% confidence interval [CI], 5.8 to 48). Regarding specific symptoms, the NNT was 11 for a 30% decrease in abdominal pain (95% CI, 5.9 to 56) and 9 for decrease in diarrhea frequency (95% CI, 5.5 to 43).

The long-term effect of rifaximin has not been studied. Relief of IBS symptoms is sustained for at least 10 weeks following treatment in about 80% of patients who initially responded.2 If symptoms recur after an initial response, retreatment is no more effective than placebo.2 No studies have evaluated retreatment in patients who do not respond to the initial treatment. No studies have directly compared rifaximin with other IBS treatments.

PRICE

A course of rifaximin costs approximately $1,400 (available only as a brand name), compared with $20 ($68) for dicyclomine (Bentyl), which is also used to relieve abdominal pain and discomfort from IBS.

SIMPLICITY

Rifaximin is given as one tablet every eight hours for 14 days.1 There is currently no indication for a repeated course of therapy.

Bottom Line

Rifaximin has good overall tolerability. A relatively short course of treatment results in sustained clinical benefit for at least 10 weeks, eliminating the need for continued therapy, with an NNT of 10. However, it is expensive and should be reserved for patients who cannot tolerate or did not respond to more affordable therapies.

Address correspondence to Sabesan Karuppiah, MD, MPH, at skaruppiah@echn.org. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.

REFERENCES

show all references

1. U.S. National Library of Medicine. DailyMed. Label: Xifaxan – rifaximin tablet. Updated November 1, 2015. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5e8e2fd-7087-4b78-9181-cc259c0be2f1. Accessed December 6, 2016....

2. Pimentel M, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med. 2006;145(8):557–563.

3. Pimentel M, et al.; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32.

4. Menees S, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome. Am J Gastroenterol. 2012;107(1):28–35.

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, MMedEd, Contributing Editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

 

 

Copyright © 2017 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Dec 1, 2018

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article